(Q33658002)

28 July 2017

title

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial (English)

1 reference

multicenter clinical trial

28 July 2017

0 references

0 references

1 reference

1 reference

Marie-Germaine Bousser

2

0 references

Eric J. Topol

1

object named as

Eric J Topol

1 reference

28 July 2017

8

Gilles Montalescot

1 reference

28 July 2017

15

Deepak L Bhatt

1 reference

28 July 2017

11

Eric Cohen

1 reference

28 July 2017

Keith A A Fox

3

1 reference

28 July 2017

Mark A Creager

4

1 reference

28 July 2017

Jean-Pierre Despres

5

1 reference

28 July 2017

J Donald Easton

6

1 reference

28 July 2017

Christian W Hamm

7

1 reference

28 July 2017

P Gabriel Steg

9

1 reference

28 July 2017

Thomas A Pearson

10

1 reference

28 July 2017

Christophe Gaudin

12

1 reference

28 July 2017

Bernard Job

13

1 reference

28 July 2017

Judith H Murphy

14

1 reference

28 July 2017

CRESCENDO Investigators

16

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

376

1 reference

28 July 2017

issue

9740

1 reference

28 July 2017

page(s)

517-523

1 reference

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Annual medical spending attributable to obesity: payer-and service-specific estimates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Impairments in endocannabinoid signaling and depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

The hope and fear of rimonabant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

SLCO1B1 variants and statin-induced myopathy--a genomewide study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960935-X

7 January 2021

10.1016/S0140-6736(10)60935-X

Identifiers

DOI

1 reference

28 July 2017

1 reference